Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 6/20 | 0.53 |
| ▸ | ACACA | Q13085 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255679 | 1.00 | CYP1A2 (0.71) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL255664 | 1.00 | CYP1A2 (0.71) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL5473681 | 0.86 | SMN1; SMN2 (0.64) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL3985690 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL619526 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL2007222 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL13778592 | 0.83 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL3721881 | 0.83 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2POLBACACBACACA | |
| SCHEMBL8309864 | 0.82 | SMN1; SMN2 (0.60) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL14521538 | 0.82 | SMN1; SMN2 (0.60) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036790-A | Chiral phosphine-acyclic phosphoramidite ligand, preparation method and application thereof | 中国科学院大连化学物理研究所 | 2026-05-15 | — | — | CN | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| CN-116249556-A | Antibody conjugation chemical inducer for degrading BRM and method thereof | 基因泰克公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4185328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022020288-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | CYP1A2 1987/4885SMN1; SMN2 3178/4885POLB 4498/4885 |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | CYP1A2 1172/4885SMN1; SMN2 3247/4885POLB 4386/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | CYP1A2 3562/4885SMN1; SMN2 1994/4885POLB 2560/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CYP1A2 1069/4885SMN1; SMN2 2049/4885POLB 1939/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | CYP1A2 164/4885SMN1; SMN2 3095/4885POLB 159/4885 |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GRIN1, GRM2, GRM1 | CYP1A2 2601/4885SMN1; SMN2 3074/4885POLB 3092/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | CYP1A2 164/4885SMN1; SMN2 3095/4885POLB 159/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | CYP1A2 1172/4885SMN1; SMN2 3247/4885POLB 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.